2016 National Hepatitis Technical Assistance Meeting

December 5th, 2016 to December 8th, 2016

Ending the Epidemics: The Role of Public Health in Hepatitis Elimination

NASTAD’s 2016 National Hepatitis Technical Assistance Meeting, sessions will  provide technical assistance and educational opportunities for health department Viral Hepatitis Prevention Coordinators (VHPC), other health department staff, as well as time for networking with one another and with invited colleagues from the federal government, Industry and partner organizations. 

Agenda

Monday, December 5, 2016

1:00 PM – 2:00 PM: RegistrationCapitol Room Lobby 
 
2:00 PM – 2:30 PM: Welcome and Meeting Overview Capitol Room
 
Murray Penner, Executive Director NASTAD (View Slides)
 
DeAnn Gruber, NASTAD Chair Louisiana Department of Health 
 
2:30 PM – 3:15 PM: Introductions
 
3:15 PM – 4:30 PM:  Group Discussions – Action, Expectations & Recommendations 
 
Small group discussions for participants to share what they are currently working on, where they would like to focus more attention, share expectations for the meeting, and identify policy and technical assistance recommendations for NASTAD 
 
4:30 PM – 5:00 PM: Ending the Epidemics: Recommendations for NASTAD 
 
5:00 PM – 6:30 PM: Networking Reception (Health Department & NASTAD Staff Only) Congressional A 
 

Tuesday, December 6, 2016

8:00 AM – 5:00 PM: Registration Capitol Room Lobby
 
8:00 AM – 9:00 AM: Breakfast (Provided)Congressional B 
 
8:00 AM – 5:00 PM: Exhibit Hall Open Congressional A 
 
9:00 AM – 10:00 AM: Welcome and Opening Remarks Capitol Room 
 
Murray Penner, Executive Director NASTAD (View Slides)
 
Federal Welcome 
 
Dr. Rich Wolitski, Director, Office of HIV/AIDS and Infectious Disease Policy Department of Health & Human Services (View Slides)  
 
Dr. Jono Mermin, Director, National Center for HIV, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and Prevention (View Slides)
 
10:00 AM – 11:00 AM: Plenary #1: Ending the Epidemics: A Focus on People who Inject Drugs Capitol Room 
 
Our public health system needs to focus greater attention and resources on preventing and controlling HCV infections, especially among people who inject drugs. This session is intended to focus on key strategies needed to prioritize serving the populations who are at highest risk for acquiring and transmitting HCV in order to drive down the incidence of HCV infections and the prevalence of HCV disease in communities. 
 
Chris Taylor, Senior Director, Hepatitis NASTAD (View Slides)
 
Katie Burk, Viral Hepatitis Coordinator, San Francisco Department of Public Health (View Slides)  
 
Chris Abert, Founder and Director Indiana Recovery Alliance 
 
11:00 AM – 12:15 PM: Plenary #2: Federal Efforts to Address Hepatitis Among People who Inject Drugs Capitol Room 
 
Federal agencies have a tremendous responsibility to lead efforts to address the prevention, control and eventual elimination of hepatitis. This responsibility includes raising awareness among the general population, developing prevention and care and treatment recommendations, and providing funding to stakeholders at the state and local level. This session will include brief updates from key federal stakeholders on their efforts to address hepatitis among people who inject drugs, and will include a discussion with meeting attendees. 
 
Dr. Rich Wolitski, Director, Office of HIV/AIDS and Infectious Disease Policy Department of Health and Human Services 
 
Dr. Sean Allen, Senior Policy Advisor, White House Office of National Drug Control Policy 
 
Dr. John Ward, Director, Division of Viral Hepatitis Centers for Disease Control and Prevention  (View Slides)  
 
12:15 PM – 1:15 PM: Networking Lunch (Provided) 
 
1:30 PM – 2:45 PM: Break Out Sessions Capitol Room 
 
Addressing the Intersection: Hepatitis, HIV and People Who Inject Drugs 
 
People who inject drugs remain the population most at risk for hepatitis C. Recent data indicate increased risk of HIV infection among this population as well. This session will include presentations on addressing the hepatitis and HIV prevention needs of people who inject drugs. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction. 
 
Magalie Lerman, Beth Weinstein Fellow NASTAD 
 
Chris Abert, Founder and Director Indiana Recovery Alliance 
 
Charles Howsare, Viral Hepatitis Prevention Coordinator Pennsylvania Department of Health 
 
Data! Data! Data! Epi Profiles, Situational Analysis, Surveillance Congressional C
 
Public health practice requires the collection and analysis of data to most effectively target public health intervention. This session will include presentations on how health departments are using data to guide their program and policy actions. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction. 
 
Ami Gandhi, Viral Hepatitis Prevention Coordinator Georgia Department of Public Health 
 
Amanda Dinwiddie, Hepatitis C Epidemiologist Georgia Department of Public Health (View Slides)
 
Nicole Kolm-Valdivia, HIV Prevention Program Evaluation Coordinator Iowa Department of Public Health 
 
Nan Haugan, Epidemiologist Virginia Department of Health (View Slides)
 
Ending Perinatal Transmission of Hepatitis B and C Congressional D
 
Recent surveillance data indicate a trend of increased perinatal transmission of hepatitis C. Similarly, perinatal hepatitis B transmission remains a problem in the U.S. This session will include presentations on perinatal hepatitis B and C transmission, and how health departments and other partners are working to end perinatal transmission. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction. 
 
John Ward, Director, Division of Viral Hepatitis Centers for Disease Control and Prevention (View Slides)  
 
Kathy Sanders, Adult Viral Hepatitis Prevention CoordinatorKentucky Department of Public Health  (View Slides)  
 
Kendra Viner, Viral Hepatitis Program Manager Philadelphia Department of Public Health 
 
Kate Moraras, Director Hep B United 
 
2:45 PM – 3:15 PM: Break – Visit Exhibits Congressional A 
 
3:15 PM – 4:15 PM: Plenary #3 – Eliminating Hepatitis is a Health Equity and Social Justice Issue Capitol Room 
 
People who inject drugs, racial and ethnic minorities and people in rural areas bear a disproportionate burden of cases of hepatitis B and C. Social determinants of health underlie why these populations experience higher rates of hepatitis. This session will include presentations and discussion on why addressing hepatitis among these communities is a health equity and social justice issue.
 
Terrance Moore, Deputy Executive Director NASTAD  (View Slides)  
 
Jasmine Tyler, Senior Policy Advisor Open Society Foundations 
 
Rachel McLean, Viral Hepatitis Prevention Coordinator California Department of Public Health 
 
4:30 PM – 5:30 PM: Discussion Sessions by Region 
 
Semi-structured discussion session for participants to “check in” on topics raised in previous sessions, explore other topics they would like to discuss and hear from peers on program challenges and strategies. 
 
Appalachia  Congressional B
Northeast  — Congressional C

Midwest  — Congressional D

West  Thornton C
 
5:30 PM – 7:30 PM: Networking Reception & Exhibits Congressional A/B 
 
8:00 PM – 10:00 PM: Optional Evening Activity – Monuments by Moonlight Meet in Hotel Lobby 
 

Wednesday, December 7, 2016

 
8:00 AM – 12:00 PM: RegistrationCapitol Room Lobby 
 
8:00 AM – 9:00 AM: Breakfast (Provided) Congressional B 
 
8:00 AM – 11:00 AM: Exhibit Hall Open Congressional A
9:00-10:15 AM: Break Out Sessions 
 
Responding to Hepatitis C in Communities of Color Congressional B

Communities of color bear a disproportionate burden of hepatitis C. This session will include presentations on programs serving African-Americans, Latinos and Native Americans. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction

 
Mariah Johnson, Senior Manager, Hepatitis/Policy & Legislative Affairs NASTAD 
 
Sally Bouse, Viral Hepatitis Prevention Coordinator Oklahoma State Department of Health 
 
Working with Community Health Centers Congressional C
 
Community Health Centers remain an important venue for hepatitis prevention services, testing, and care and treatment. This session will include presentations on how health departments are working with individual health centers as well as state primary care associations. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction. 
 
Andrea Lombard, Hepatitis Coordinator Connecticut Department of Public Health 
 
Patricia Young, HIV and Hepatitis Prevention Program Manager Iowa Department of Public Health 
 
Addressing Hepatitis in Jails and Prisons: A Key Strategy to Elimination Capitol Room 
 
Incarcerated populations bear a disproportionate burden of hepatitis C infections. Jails and prisons are key venues to reach individuals with hepatitis prevention, testing and care and treatment services. This session will include presentations on how a health department is working with jails and prisons to better meet the needs of incarcerated populations. The presentations will be followed by a group discussion of how participants are addressing this issue in their jurisdiction. 
 
Stephanie McHugh, Health Program Administrator New York State Department of Health (View Slides)  
 
Megan Haseltine, Hepatitis C Screening Coordinator New York State Department of Health 
 
Elizabeth Paukstis, Public Policy Director National Viral Hepatitis Roundtable (View Slides)
 
10:30 AM – 11:30 AM: Plenary #4: The Role of Treatment in Hepatitis EliminationCapitol Room 
 
With the advent of highly effective direct acting antiviral medications which cure hepatitis C in the majority of patients, it is essential that we consider the role of treatment as prevention in addressing and eliminating hepatitis C. Unfortunately, there remain barriers and challenges to everyone needing treatment receiving them. This session will include presentations and discussion on the role of hepatitis C treatment as prevention, an examination of which state Medicaid programs continue to deny treatment to beneficiaries – and why, and what needs to occur to ensure that everyone living with hepatitis C has access to these effective treatments. 
 
Ryan Clary, Executive Director National Viral Hepatitis Roundtable (View Slides)  
 
John Ward, Director, Division of Viral Hepatitis Centers for Disease Control and Prevention (View Slides)
11:30 AM - 12:00 PM: Closing Remarks – End of Meeting Capitol Room 
 
Chris Taylor, Senior Director, Hepatitis NASTAD 
 
Meeting Participants 
 
12:00 PM – 1:00 PM: Lunch (On Your Own)
 
1:00 PM – 4:00 PM: CDC Meeting with Health Departments (Closed) Capitol Room

 

Thursday, December 8, 2016

9:00 AM – 2:00 PM: Educational Hill Visits